Adapalene


Mayne Pharma Inc.
Human Prescription Drug
NDC 68308-706
Adapalene is a human prescription drug labeled by 'Mayne Pharma Inc.'. National Drug Code (NDC) number for Adapalene is 68308-706. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Adapalene drug includes Adapalene - 1 mg/g . The currest status of Adapalene drug is Active.

Drug Information:

Drug NDC: 68308-706
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Adapalene
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Adapalene
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mayne Pharma Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ADAPALENE - 1 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 20 Apr, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA090824
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Mayne Pharma Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:313852
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0368308706452
UPC stands for Universal Product Code.
NUI:N0000175607
M0018962
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:1L4806J2QF
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Retinoid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Retinoids [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Retinoid [EPC]
Retinoids [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68308-706-451 TUBE in 1 CARTON (68308-706-45) / 45 g in 1 TUBE20 Apr, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Adapalene adapalene adapalene adapalene carbomer homopolymer type b (allyl sucrose crosslinked) cyclomethicone edetate disodium glycerin methylparaben phenoxyethanol propylparaben water squalene trolamine methyl glucose sesquistearate peg-20 methyl glucose sesquistearate

Drug Interactions:

Drug interactions: as adapalene cream has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime rind) should be approached with caution. particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene cream. if these preparations have been used, it is advisable not to start therapy with adapalene cream until the effects of such preparations in the skin have subsided.

Indications and Usage:

Indications and usage: adapalene cream is indicated for the topical treatment of acne vulgaris.

General Precautions:

General: certain cutaneous signs and symptoms of treatment such as erythema, dryness, scaling, burning, or pruritus may be experienced with use of adapalene cream. these are most likely to occur during the first two to four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication. depending upon the severity of these side effects, patients should be instructed to reduce the frequency of application or discontinue use. if a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. exposure to sunlight, including sunlamps, should be minimized during use of adapalene. patients who normally experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise caution. use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. weather extremes, such as wind or cold, also may be irr
itating to patients under treatment with adapalene. avoid contact with the eyes, lips, angles of the nose, and mucous membranes. the product should not be applied to cuts, abrasions, eczematous or sunburned skin. as with other retinoids, use of "waxing" as a depilatory method should be avoided on skin treated with adapalene.

Dosage and Administration:

Dosage and administration: adapalene cream should be applied to affected areas of the skin, once daily at nighttime. a thin film of the cream should be applied to the skin areas where acne lesions appear, using enough to cover the entire affected area lightly. a mild transitory sensation of warmth or slight stinging may occur shortly after the application of adapalene cream.

Contraindications:

Contraindications: adapalene cream should not be administered to individuals who are hypersensitive to adapalene or any of the components in the cream vehicle.

Adverse Reactions:

Adverse reactions: in controlled clinical trials, local cutaneous irritation was monitored in 285 acne patients who used adapalene cream once daily for 12 weeks. the frequency and severity of erythema, scaling, dryness, pruritus and burning were assessed during these studies. the incidence of local cutaneous irritation with adapalene cream from the controlled clinical studies is provided in the following table: incidence of local cutaneous irritation with adapalene cream from controlled clinical studies (n=285) none mild moderate severe erythema 52% (148) 38% (108) 10% (28) <1% (1) scaling 58% (166) 35% (100) 6% (18) <1% (1) dryness 48% (136) 42% (121) 9% (26) <1% (2) pruritis (persistent) 74% (211) 21% (61) 4% (12) <1% (1) burning/stinging (persistent) 71% (202) 24% (69) 4% (12) <1% (2) other reported local cutaneous adverse events in patients who used adapalene cream once daily included: sunburn (2%), skin discomfort-burning and stinging (1%) and skin irritation (1%). events occurrin
g in less than 1% of patients treated with adapalene cream included: acne flare, dermatitis and contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.

Adverse Reactions Table:

Incidence of Local Cutaneous Irritation with Adapalene Cream from Controlled Clinical Studies (N=285)
NoneMildModerateSevere
Erythema 52% (148) 38% (108) 10% (28) <1% (1)
Scaling 58% (166) 35% (100) 6% (18) <1% (1)
Dryness 48% (136) 42% (121) 9% (26) <1% (2)
Pruritis (persistent) 74% (211) 21% (61) 4% (12) <1% (1)
Burning/Stinging (persistent) 71% (202) 24% (69) 4% (12) <1% (2)

Drug Interactions:

Drug interactions: as adapalene cream has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime rind) should be approached with caution. particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene cream. if these preparations have been used, it is advisable not to start therapy with adapalene cream until the effects of such preparations in the skin have subsided.

Use in Pregnancy:

Pregnancy: teratogenic effects. pregnancy category c. no teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene (up to 20 times the mrhd based on mg/m 2 comparisons). however, adapalene administered orally at doses of ≥ 25 mg/kg, (100 times the mrhd for rats or 200 times mrhd for rabbits) has been shown to be teratogenic. cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day (24 times the mrhd for rats or 48 times the mrhd for rabbits) exhibited no fetotoxicity and only minimal increases in supernumerary ribs in rats. there are no adequate and well-controlled studies in pregnant women. adapalene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Pediatric use: safety and effectiveness in pediatric patients below the age of 12 have not been established.

Geriatric Use:

Geriatric use: clinical studies of adapalene cream were conducted in patients 12 to 30 years of age with acne vulgaris and therefore did not include subjects 65 years and older to determine whether they respond differently than younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Overdosage:

Overdosage: adapalene cream is intended for cutaneous use only. if the medication is applied excessively, no more rapid or better results will be obtained and marked redness, scaling, or skin discomfort may occur. the acute oral toxicity of adapalene cream in mice and rats is greater than 10 ml/kg. chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin a.

Description:

Description: adapalene cream, 0.1%, contains adapalene 0.1% in an aqueous cream emulsion consisting of carbomer 934p, cyclomethicone, edetate disodium, glycerin, methyl glucose sesquistearate, methylparaben, peg-20 methyl glucose sesquistearate, phenoxyethanol, propylparaben, purified water, squalane, and trolamine. the chemical name of adapalene is 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid. it is a white to off-white powder which is soluble in tetrahydrofuran, sparingly soluble in ethanol, and practically insoluble in water. the molecular formula is c 28 h 28 o 3 and molecular weight is 412.52. adapalene is represented by the following structural formula: structural formula

Clinical Pharmacology:

Clinical pharmacology: mechanism of action: adapalene acts on retinoid receptors. biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein. although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. pharmacokinetics: absorption of adapalene from adapalene cream through human skin is low. in a pharmacokinetic study with six acne patients treated once daily for 5 days with 2 grams of adapalene cream applied to 1000 cm 2 of acne involved skin, there were no quantifiable amounts (limit of quantification = 0.35 ng/ml) of adapalene in
the plasma samples from any patient. excretion appears to be primarily by the biliary route.

Mechanism of Action:

Mechanism of action: adapalene acts on retinoid receptors. biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein. although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.

Pharmacokinetics:

Pharmacokinetics: absorption of adapalene from adapalene cream through human skin is low. in a pharmacokinetic study with six acne patients treated once daily for 5 days with 2 grams of adapalene cream applied to 1000 cm 2 of acne involved skin, there were no quantifiable amounts (limit of quantification = 0.35 ng/ml) of adapalene in the plasma samples from any patient. excretion appears to be primarily by the biliary route.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, and impairment of fertility: carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day, and in rats at oral doses of 0.15, 0.5, and 1.5 mg/kg/day. these doses are up to 8 times (mice) and 6 times (rats) in terms of mg/m 2 /day the maximum potential exposure at the recommended topical human dose (mrhd), assumed to be 2.5 grams adapalene cream, which is approximately 1.5 mg/m 2 adapalene. in the oral study, increased incidence of benign and malignant pheochromocytomas in the adrenal medullas of male rats was observed. no photocarcinogenicity studies were conducted. animal studies have shown an increased risk of skin neoplasms with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to uv irradiation in the laboratory or to sunlight. although the significance of these studies to human use is not clear, patients should be advised to avoid or minimize exposure to either sunlight or ar
tificial uv irradiation sources. adapalene did not exhibit mutagenic or genotoxic effects in vivo (mouse micronucleous test) and in vitro (ames test, chinese hamster ovary cell assay, mouse lymphoma tk assay) studies. reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts up to 20 mg/kg/day (up to 80 times the mrhd based on mg/m 2 comparisons). no effects of adapalene were found on the reproductive performance or fertility of the fo males or females. there were also no detectable effects on the growth, development and subsequent reproductive function of the f 1 generation.

Clinical Studies:

Clinical studies: two vehicle-controlled clinical studies were conducted in patients 12 to 30 years of age with mild to moderate acne vulgaris, in which adapalene cream was compared with its vehicle. patients were instructed to apply their treatment medication once daily at bedtime for 12 weeks. in one study patients were provided with a soapless cleanser and were encouraged to refrain from using moisturizers. no other topical medications, other than adapalene cream, were to be applied to the face during the studies. adapalene cream was significantly more effective than its vehicle in the reduction of acne lesion counts. the mean percent reduction in lesion counts from baseline after treatment for 12 weeks are presented in the following table: mean percent reduction in lesion counts from baseline to week 12 study no. 1 study no. 2 efficacy variable adapalene cream, 0.1% n=119 cream vehicle n=118 adapalene cream, 0.1% n=175 cream vehicle n=175 non-inflammatory lesions 34% 18% 35% 15% in
flammatory lesions 32% 17% 14% 6% total lesions 34% 18% 30% 15% the trend in the investigator's global assessment of severity supported the efficacy of adapalene cream when compared to the cream vehicle.

How Supplied:

How supplied: adapalene cream, 0.1% is supplied in a 45 g tube - ndc 68308-706-45 storage: store at controlled room temperature 68° to 77°f (20° to 25°c). excursions permitted between 59° to 86° f (15° to 30° c). protect from freezing. 46291695a rev. 06/2021 #174 to report suspected adverse reactions, contact sandoz inc. at 1-800-525-8747 or fda at 1-800-fda-1088 or http://www.fda.gov/medwatch . distributed by: mayne pharma greenville, nc 27834

Information for Patients:

Information for patients: patients using adapalene cream should receive the following information and instructions: 1. this medication is to be used only as directed by the physician. 2. it is for external use only. 3. avoid contact with the eyes, lips, angles of the nose, and mucous membranes. 4. cleanse area with a mild or soapless cleanser before applying this medication. 5. moisturizers may be used if necessary, however, products containing alpha hydroxy or glycolic acids should be avoided. 6. exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis, and eye irritation. 7. this medication should not be applied to cuts, abrasions, eczematous or sunburned skin. 8. wax epilation should not be performed on treated skin due to the potential for skin erosions. 9. during the early weeks of therapy, an apparent exacerbation of acne may occur. this is due to the action of this medication on previously unseen lesions and should not be considered a reaso
n to discontinue therapy. overall clinical benefit may be noticed after two weeks of therapy, but at least eight weeks are required to obtain consistent beneficial effects.

Package Label Principal Display Panel:

Package label – principal display panel – 45g container ndc 68308-706-45 mayne pharma adapalene cream 0.1% rx only for topical use only. not for ophthalmic, oral or intravaginal use. net wt 45 grams tube45g

Package label – principal display panel – 45g carton ndc 68308-706-45 rx only mayne pharma adapalene cream 0.1% for topical use only. not for ophthalmic, oral, or intravaginal use. net wt 45 grams carton45g


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.